Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

578 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock.
Barrett JJE, Herzog C, Kim YN, Bartlett TE, Jones A, Evans I, Cibula D, Zikan M, Bjørge L, Harbeck N, Colombo N, Howell SJ, Rådestad AF, Gemzell-Danielsson K, Widschwendter M. Barrett JJE, et al. Among authors: colombo n. Genome Biol. 2022 Jun 29;23(1):142. doi: 10.1186/s13059-022-02704-z. Genome Biol. 2022. PMID: 35768851 Free PMC article. No abstract available.
The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership.
Marth C, du Bois A, Schauer C, du Bois A, Casado A, Vergote I, del Campo JM, Goudopoulou A, Pujade-Lauraine E, Bruchim I, Colombo N, Pignata S, Ledermann J, Chekerov R, Raza Mirza M, Westermann A, Glasspool R, Taskiran C, Fehr M, Cibula D. Marth C, et al. Among authors: colombo n. Int J Gynecol Cancer. 2015 Jul;25(6):1094-5. doi: 10.1097/IGC.0000000000000446. Int J Gynecol Cancer. 2015. PMID: 26098090 No abstract available.
Follow-up in Gynecological Malignancies: A State of Art.
Zola P, Macchi C, Cibula D, Colombo N, Kimmig R, Maggino T, Reed N, Kesic V. Zola P, et al. Among authors: colombo n. Int J Gynecol Cancer. 2015 Sep;25(7):1151-64. doi: 10.1097/IGC.0000000000000498. Int J Gynecol Cancer. 2015. PMID: 26207784 Review.
Epigenome-based cancer risk prediction: rationale, opportunities and challenges.
Widschwendter M, Jones A, Evans I, Reisel D, Dillner J, Sundström K, Steyerberg EW, Vergouwe Y, Wegwarth O, Rebitschek FG, Siebert U, Sroczynski G, de Beaufort ID, Bolt I, Cibula D, Zikan M, Bjørge L, Colombo N, Harbeck N, Dudbridge F, Tasse AM, Knoppers BM, Joly Y, Teschendorff AE, Pashayan N; FORECEE (4C) Consortium. Widschwendter M, et al. Among authors: colombo n. Nat Rev Clin Oncol. 2018 May;15(5):292-309. doi: 10.1038/nrclinonc.2018.30. Epub 2018 Feb 27. Nat Rev Clin Oncol. 2018. PMID: 29485132 Review.
Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study.
Nené NR, Reisel D, Leimbach A, Franchi D, Jones A, Evans I, Knapp S, Ryan A, Ghazali S, Timms JF, Paprotka T, Bjørge L, Zikan M, Cibula D, Colombo N, Widschwendter M. Nené NR, et al. Among authors: colombo n. Lancet Oncol. 2019 Aug;20(8):1171-1182. doi: 10.1016/S1470-2045(19)30340-7. Epub 2019 Jul 9. Lancet Oncol. 2019. PMID: 31300207
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
Ray-Coquard I, Cibula D, Mirza MR, Reuss A, Ricci C, Colombo N, Koch H, Goffin F, González-Martin A, Ottevanger PB, Baumann K, Bjørge L, Lesoin A, Burges A, Rosenberg P, Gropp-Meier M, Harrela M, Harter P, Frenel JS, Minarik T, Pisano C, Hasenburg A, Merger M, du Bois A; AGO Study Group-led GCIG/ENGOT Intergroup Consortium. Ray-Coquard I, et al. Among authors: colombo n. Int J Cancer. 2020 Jan 15;146(2):439-448. doi: 10.1002/ijc.32606. Epub 2019 Sep 6. Int J Cancer. 2020. PMID: 31381147 Free article. Clinical Trial.
DNA methylation signatures to predict the cervicovaginal microbiome status.
Nené NR, Barrett J, Jones A, Evans I, Reisel D, Timms JF, Paprotka T, Leimbach A, Franchi D, Colombo N, Bjørge L, Zikan M, Cibula D, Widschwendter M. Nené NR, et al. Among authors: colombo n. Clin Epigenetics. 2020 Nov 23;12(1):180. doi: 10.1186/s13148-020-00966-7. Clin Epigenetics. 2020. PMID: 33228781 Free PMC article.
The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples.
Barrett JE, Herzog C, Jones A, Leavy OC, Evans I, Knapp S, Reisel D, Nazarenko T, Kim YN, Franchi D, Ryan A, Franks J, Bjørge L, Zikan M, Cibula D, Harbeck N, Colombo N, Dudbridge F, Jones L, Sundström K, Dillner J, Rådestad AF, Gemzell-Danielsson K, Pashayan N, Widschwendter M. Barrett JE, et al. Among authors: colombo n. Nat Commun. 2022 Feb 1;13(1):449. doi: 10.1038/s41467-021-27918-w. Nat Commun. 2022. PMID: 35105882 Free PMC article.
Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock.
Barrett JE, Herzog C, Kim YN, Bartlett TE, Jones A, Evans I, Cibula D, Zikan M, Bjørge L, Harbeck N, Colombo N, Howell SJ, Rådestad AF, Gemzell-Danielsson K, Widschwendter M. Barrett JE, et al. Among authors: colombo n. Genome Biol. 2022 Feb 22;23(1):52. doi: 10.1186/s13059-022-02603-3. Genome Biol. 2022. PMID: 35189945 Free PMC article.
The WID-EC test for the detection and risk prediction of endometrial cancer.
Barrett JE, Jones A, Evans I, Herzog C, Reisel D, Olaitan A, Mould T, MacDonald N, Doufekas K, Newton C, Crosbie EJ, Bjørge L, Colombo N, Dostalek L, Costas L, Peremiquel-Trillas P, Ponce J, Matias-Guiu X, Zikan M, Cibula D, Wang J, Sundström K, Dillner J, Widschwendter M. Barrett JE, et al. Among authors: colombo n. Int J Cancer. 2023 May 1;152(9):1977-1988. doi: 10.1002/ijc.34406. Epub 2023 Jan 17. Int J Cancer. 2023. PMID: 36533702 Free article.
578 results